日前，美国生物制药公司吉利德公布Lenacapavir（来那卡帕韦）预防 HIV 的临床试验结果，显示出100%的有效性。 最新公布的结果是一项名为PURPOSE 1的III ...

2024年6月，吉利德科学（Gilead Sciences）公司宣布，其每半年注射一次的HIV-1衣壳抑制剂lenacapavir，在女性群体中预防HIV的临床试验里显示出100%的优效性。

Lenacapavir’s efficacy was demonstrated ... Because of its innovative mechanism and extended dosing schedule it has been described as a pathbreaking advancement in HIV care and is being heralded ...

When the next patient asks me about a game-changing HIV prevention tool, I hope I can say, “It’s already here and available to everyone who needs it.” ...

【吉利德科学研发的“Lenacapavir”在预防艾滋病毒方面显示出 100%有效性】 据每经，当地时间周四，美国生物制药公司吉利德科学在其官网公布实验 ...

Gilead Sciences has refiled for FDA approval of its HIV capsid inhibitor lenacapavir – which only needs to be dosed every six months – after the drug was rejected by the regulator in February.

Recent research has focused on innovative treatment options, particularly the development of new classes of antiretroviral drugs, such as lenacapavir, which is a first-in-class capsid inhibitor.

Lenacapavir (previously GS-6207) is the first in a new class of class HIV-1 capsid inhibitor that Gilead is hoping will eventually free patients from the need to take daily oral tablets, although ...

Lenacapavir 463.5mg/1.5mL (309mg/mL); soln for SC inj; preservative-free. Lenacapavir is a multistage, selective inhibitor of HIV-1 capsid function that directly binds to the interface between ...

The firm highlighted that Gilead's shares have seen a rise due to positive developments in its pipeline, particularly for Lenacapavir in HIV prevention and anito-cel in multiple myeloma.